Is the shingles vaccine recommended for adults with Crohn's disease, particularly those receiving immunosuppressive therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Shingles Vaccine is Strongly Recommended for Adults with Crohn's Disease

Yes, the recombinant zoster vaccine (Shingrix/RZV) should be given to all adults with Crohn's disease aged 50 or older who are receiving immunomodulators or advanced therapies, and to those aged 18 or older starting JAK inhibitors. 1

Key Vaccination Recommendations

Who Should Receive the Vaccine

The recombinant zoster vaccine (Shingrix) is the only appropriate shingles vaccine for immunosuppressed Crohn's patients. The live zoster vaccine (Zostavax) is absolutely contraindicated in anyone receiving immunosuppressive therapy. 1

Specific indications:

  • All patients aged ≥50 years receiving any immunomodulators or advanced therapies 1
  • All patients aged ≥18 years starting JAK inhibitors 1
  • All adults aged ≥19 years receiving or planning to initiate immune-modifying therapies 2
  • All adults aged ≥50 years regardless of therapy status are now eligible 1

Why This Matters

Patients with Crohn's disease face substantially elevated herpes zoster risk due to both intrinsic immune dysregulation and immunosuppressive medications. Recent high-quality evidence demonstrates that RZV reduces herpes zoster complications by 25% (HR 0.75) in IBD patients, with particularly dramatic reductions in postherpetic neuralgia (34% reduction, HR 0.66). 3 Another 2025 study showed 65% vaccine effectiveness in preventing herpes zoster in adults ≥50 with IBD. 4

Critical Safety Information

RZV does not increase the risk of Crohn's disease flares. A rigorous self-controlled case series analysis found no increased flare risk within 30 days of vaccination (RR 0.80,95% CI 0.47-1.35). 4 This addresses a common concern that prevents appropriate vaccination.

Immunosuppressive Therapy Definitions

Immunosuppressive therapies that trigger the need for RZV include:

  • Corticosteroids (prednisolone ≥20 mg/day or equivalent for ≥2 weeks)
  • Purine analogues (azathioprine, mercaptopurine)
  • Methotrexate
  • All biologic therapies (anti-TNF, anti-integrin, anti-IL-12/23)
  • JAK inhibitors (particularly important—vaccinate at age 18+)
  • Other advanced therapies 1

Timing Considerations

RZV can be administered safely during ongoing immunosuppressive therapy because it is a recombinant (non-live) vaccine. There is no need to hold immunosuppressive medications or wait for treatment windows. 1

Optimal timing:

  • Ideally administer before starting immunosuppressive therapy when possible
  • Can be given during active immunosuppression without safety concerns
  • Two-dose series required (typically 2-6 months apart)

Common Pitfalls to Avoid

  1. Do not confuse RZV (Shingrix) with ZVL (Zostavax). The live vaccine Zostavax is contraindicated in immunosuppressed patients. Only the recombinant vaccine Shingrix is appropriate. 1

  2. Do not delay vaccination waiting for "ideal" timing. While vaccine efficacy may be somewhat reduced during active immunosuppression, the benefits far outweigh waiting, and the vaccine remains effective. 1

  3. Do not restrict vaccination to older patients only. The 2025 British Society of Gastroenterology guidelines explicitly recommend vaccination starting at age 50 for those on immunomodulators, and age 18 for those starting JAK inhibitors. 1

  4. Do not assume prior chickenpox or shingles precludes vaccination. RZV is recommended regardless of prior varicella vaccination status or history of herpes zoster. 2

Expected Adverse Effects

Patients should be counseled that RZV causes more injection-site reactions and systemic symptoms than many other vaccines:

  • Grade 3 injection-site reactions: 9.5% vs 0.4% placebo
  • Grade 3 systemic symptoms: 11.4% vs 2.4% placebo
  • No increase in serious adverse events or deaths 5

These reactions, while uncomfortable, are self-limited and do not represent disease flares or vaccine failure.

Integration with Other Vaccinations

RZV should be part of a comprehensive vaccination strategy for Crohn's patients that includes:

  • Annual inactivated influenza vaccine
  • Pneumococcal vaccination with 5-year booster
  • 6-monthly SARS-CoV-2 vaccination (adjusted to current recommendations)
  • Hepatitis B vaccination for seronegative patients 1

References

5
Guideline

recommendations and guidance for herpes zoster vaccination for adults in taiwan.

Journal of Microbiology, Immunology and Infection, 2024

Related Questions

What is the first-line treatment for a 13-year-old female with Crohn disease presenting with chronic diarrhea and altered bowel habits for 3–4 months and colonoscopic findings of transmural inflammation?
In a 68-year-old man with Crohn disease on postoperative day 2 after small bowel resection who presents with hematochezia, hypotension, tachycardia, severe anemia, and a poor pulse oximetry waveform, what is the most likely cause of the unreliable pulse oximetry readings?
What antibiotics are safe for an adult patient with Crohn’s disease who has no known drug allergies?
What are the appropriate antibiotics for an adult with Crohn disease who requires treatment for an acute flare, suspected bacterial overgrowth, perianal abscess, or fistula?
What is the best emergency department treatment plan for a 67-year-old male with a history of Crohn's disease presenting with abdominal pain and CT findings of acute on chronic inflammation?
Can aspirin (acetylsalicylic acid), clopidogrel, and atorvastatin cause acute tubular necrosis or acute kidney injury?
What oral and intranasal anti‑MRSA medications should I prescribe for a patient with cellulitis of the nose and a prior history of MRSA colonization?
What is the appropriate prophylactic antibiotic regimen for a patient with a tick bite that was attached for more than 36 hours in a Lyme‑endemic area, assuming the patient is not pregnant, not allergic to tetracyclines, and is older than 8 years?
Is it safe to use baclofen and cyclobenzaprine (Flexeril) together?
What is the safest NSAID for short-term therapy in older adults (≥ 65 years)?
What are the best stool softeners for hemorrhoids?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.